Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability
Journal of Medicinal Chemistry · 13.04.2023 · 66 (7) · 4849-4867
DOI: 10.1021/acs.jmedchem.2c02006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.03.2023. Verfasst von Silong Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, P. R. China. Hauptthemen laut MEDLINE: Methionine Adenosyltransferase, Colonic Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Tianjin Municipal Science and Technology Bureau, National Natural Science Foundation of China, Wuhan Yuxiang Pharmaceutial Technology Co., Ltd..
Abstract (Originalsprache)
Inhibition of methionine adenosyltransferase 2A (MAT2A) in cancers with a deletion of methylthioadenosine phosphorylase (MTAP) gene leads to synthetic lethality, thus receiving significant interest in the field of precise cancer treatment. Herein, we report the discovery of a tetrahydrobenzo[4,5]imidazo[1,2-a]pyrazine fragment which occupies the MAT2A allosteric pocket. The lead compound 8 exhibited extremely high potency to inhibit MAT2A enzymatic activity (IC50 = 18 nM) and proliferation of MTAP-null cancer cells (IC50 = 52 nM). 8 had a favorable pharmacokinetic profile with a bioavailability of 116% in mice. More importantly, introducing an amide motif (28) to the core structure raised the plasma drug exposure from 11 718 to 41 192 ng·h·mL-1. 28 displayed a significantly better in vivo potency than AG-270, which is being evaluated in clinical trails, and induced -52% tumor regression in a xenograft MTAP-depleted colon tumor model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, P. R. China.
- Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, College of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, P. R. China.
- Wuhan Yuxiang Pharmaceutical Technology Company, Limited, Wuhan 430200, P. R. China.
- School of Life Science and Technology & School of Chemical and Environmental Engineering, Wuhan Polytechnic University, Wuhan 430023, P. R. China.
- Hubei Key Laboratory of Radiation Chemistry and Functional Materials, Hubei University of Science and Technology, Xianning 437100, P. R. China.
ORCID-Profile: Silong Zhang, Yi Liu
Förderung
- Tianjin Municipal Science and Technology Bureau
- National Natural Science Foundation of China
- Wuhan Yuxiang Pharmaceutial Technology Co., Ltd.
Zitieren
APA
Zhang, S., Qing, L., Wang, Z., Zhang, Y., Li, Y., Fang, H., Liu, Y., & He, H. (2023). Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability. Journal of Medicinal Chemistry, 66(7), 4849-4867. https://doi.org/10.1021/acs.jmedchem.2c02006
Vancouver
Zhang S, Qing L, Wang Z, Zhang Y, Li Y, Fang H, et al. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability. Journal of Medicinal Chemistry. 2023;66(7):4849-4867. doi:10.1021/acs.jmedchem.2c02006
BibTeX
@article{Zhang2023,
author = {Zhang, Silong and Qing, Luolong and Wang, Ziwei and Zhang, Yu and Li, Yuanyuan and Fang, Huaxiang and Liu, Yi and He, Huan},
title = {Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {7},
pages = {4849--4867},
doi = {10.1021/acs.jmedchem.2c02006}
}
EUVIMED